(-)-3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid | 223607-27-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: (-)-3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid
• 英文别名: (2S)-3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid
• CAS: 223607-27-0
• 化学式: C₂₁H₂₅NO₄S
• 分子量: 387.5
• InChiKey: GKBWKSJWXJMEEQ-IBGZPJMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  84.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (-)-3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以50%的产率得到(-)-3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid, sodium salt
  参考文献：
  名称：

  Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents

  摘要：

  本发明涉及新型抗肥胖和降低胆固醇的化合物、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和药学上可接受的含有它们的组合物。更具体地，本发明涉及一般式(I)的新型β-芳基-α-氧代取代烷基羧酸、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和药学上可接受的含有它们的组合物。

  公开号：

  US07348426B1
• 作为产物：
  描述：

  ethyl (2R)-2-ethoxy-3-(4-hydroxyphenyl)propanoate 在 sodium hydroxide 、 水 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.66h， 生成 (-)-3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid
  参考文献：
  名称：

  Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents

  摘要：

  本发明涉及新型抗肥胖和降低胆固醇的化合物、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和药学上可接受的含有它们的组合物。更具体地，本发明涉及一般式(I)的新型β-芳基-α-氧代取代烷基羧酸、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和药学上可接受的含有它们的组合物。

  公开号：

  US07348426B1

文献信息

• Pharmaceutical composition and method for the treatment of diseases using HMG-CoA reductase inhibitors and insulin secretion enhancers or sensitizers
  申请人：Damon Edson Robert

  公开号：US20070027197A1

  公开（公告）日：2007-02-01

  The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) a HMG-CoA reductase inhibitor or a or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or  (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier.
• Combination of nateglinide or repaglinide with at least one further antidiabetic compound
  申请人：Villhauer Edwin Bernard

  公开号：US20080261864A1

  公开（公告）日：2008-10-23

  The present invention relates to a combination of organic compounds which comprises at least two antidiabetic agents, preferably with different modes of action, in which the active ingredients are in each case present in free form or in the form of a pharmaceutically acceptable salt and, optionally, at least on pharmaceutically acceptable carrier, for simultaneous, separate or sequential use.
• SALTS OF NATEGLINIDE
  申请人：Sutton Paul Allen

  公开号：US20090143469A1

  公开（公告）日：2009-06-04

  The present invention relates to salts of organic acid, in particular salt of nateglinide, combined preparations comprising one or more salts of nateglinide and, optionally, one or more additional ingredients and the use thereof in pharmaceutical compositions for preventing or treating diabetes, cardiovascular disease, or conditions associated therewith.
• US7348426B1
  申请人：——

  公开号：US7348426B1

  公开（公告）日：2008-03-25
• [EN] PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS<br/>[FR] DERIVES DU PYRANNE UTILISES COMME INHIBITEURS DE ACE ET NEP
  申请人：NOVARTIS AG

  公开号：WO2003027091A1

  公开（公告）日：2003-04-03

  Compounds of the formula (I), wherein R1, R1-R7 and alk have meaning as defined, pharmaceutical compositions thereof, and use thereof for the treatment and/or prevention of cardiovascular disorders responsive to ACE and NEP inhibition and/or ECE inhibition.